UK Medical Devices Agency (MDA) rates erythropoietin (EPO) kits
This article was originally published in Clinica
Executive Summary
ELISA and EIA erythropoietin tests have lower limits of detection but RIAs are easier to use, says a survey by the UK Medical Devices Agency (MDA). The agency evaluated six erythropoietin (EPO) kits: RIAs from Incstar, Ramco Laboratories and Diagnostic Systems Laboratories; an EIA from bioMerieux; and ELISAs by IBL and Medac. Incstar's EPO-Trac RIA was used as the reference test. Nichols Institute's CLIA kit was initially included, but was discounted when the company withdrew it from the market. A new version was launched in May 1995.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.
Pair Of Deaths Linked To Recalled Vyaire Medical Respiratory Devices
The US FDA has labelled a recall of more than 6 million Airlife respiratory support devices class I. The recall covers devices manufactured in 2017 or earlier that can fail to provide adequate ventilation.
Over The Counter 2 Apr 2024: Analyzing The Spin-Out Trend In Consumer Health, With HBW’s Malcolm Spicer And Tom Gallen
In this episode, HBW Insight’s Europe and US editors bring their expertise to bear on the current the trend towards standalone OTC companies in global consumer health. We look at four major players: Haleon, which separated from GSK almost two years ago; Kenvue, soon to celebrate its first anniversary as a new company; Sanofi Consumer Healthcare, which is poised to split from its pharma parent; and Bayer, which has decided to buck the trend, holding on to its consumer health division. We discuss some of the advantages of becoming a standalone company, for example in leaning into a wider concept of self-care.